Q-omics provides the consensus-scored DPPA3 profile across patient tissues and cancer cell-line models. DPPA3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DPPA3 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, DPPA3 RNA expression shows 7,274 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LUSC, and TGCT as cancer lineages where DPPA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPPA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPPA3 survival associations across molecular data types. DPPA3 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPPA3 RNA expression–survival associations across cancer types. High DPPA3 expression shows unfavorable associations in ACC, KIRC, MESO, LUSC, UCS and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DPPA3 RNA expression.
This table summarizes DPPA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for DPPA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPPA3 shows lower tumor expression in LUSC and THCA and higher tumor expression in ESCA and HNSC. The LUSC box plot shows higher DPPA3 RNA expression in normal versus tumor tissue (log2 FC = −0.151, t-test p < 0.001).
This table shows molecular features associated with DPPA3 in patient tissues and cancer cell lines. In patient samples, DPPA3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DPPA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
